ORPOF (OSE Immunotherapeutics) Short Ratio


ORPOF OSE Immunotherapeutics SA ORPOF
41 GF Score
Price $4.43
GF Value $1.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ORPOF
41GF Score
OSE Immunotherapeutics SA ORPOF
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OSE Immunotherapeutics (ORPOF) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of $4.43 is trading 151.7% above its estimated GF Value™ of $1.76. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for ORPOF:

  • Short Ratio:
  • GF Value™: $1.76 vs. price of $4.43 (151.7% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the ORPOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
41GF Score

Get the complete analysis for ORPOF

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.43
Price
$1.76
GF Value